1,217 results match your criteria Esthesioneuroblastoma


Application of the subdural evacuating port system for the drainage of postoperative tension pneumocephalus: A technical note.

Surg Neurol Int 2022 20;13:204. Epub 2022 May 20.

Department of Neurosurgery, Lenox Hill Hospital, New York City, New York, United States.

Background: Tension pneumocephalus is a neurosurgical emergency requiring prompt intervention. A variety of either temporizing or definitive methods was previously described as part of its management. Here, we report on an off-label use of a bed-side device and the subdural evacuating port system (SEPS)™ for the treatment of tension pneumocephalus. Read More

View Article and Full-Text PDF

Frontal lobe position after single-layer cadaveric dermal matrix repair of large anterior skull base defects.

World J Otorhinolaryngol Head Neck Surg 2022 Mar 31;8(1):36-41. Epub 2022 Mar 31.

Rhinology & Skull Base Surgery, Department of Otolaryngology University of Miami Miller School of Medicine Miami Florida USA.

Objective: Endoscopic repair of large anterior skull base (ASB) defects has excellent results when using multilayered repairs with a nasoseptal flap. However, in extensive intranasal tumors, a nasoseptal flap may not always be available. One alternative option is a flexible single-layer ASB repair. Read More

View Article and Full-Text PDF

Exclusively endoscopic surgical resection of esthesioneuroblastoma: A systematic review.

World J Otorhinolaryngol Head Neck Surg 2022 Mar 22;8(1):66-72. Epub 2022 Mar 22.

Department of Otolaryngology-Head and Neck Surgery New York-Presbyterian Hospital-Columbia University Irving Medical Center New York New York USA.

Background: Historically sinonasal malignancies were always addressed via open craniofacial surgery for an oncologic resection. Increasingly esthesioneuroblastomas are excised using an exclusively endoscopic approach, however, the rarity of this disease limits the availability of long-term and large scale outcomes data.

Objective: The primary objective is to evaluate the treatment modalities used and the overall survival of patients with esthesioneuroblastoma managed with exclusively endoscopic surgery. Read More

View Article and Full-Text PDF

Olfactory Neuroblastomas: What Actually Happens in the Long-Term?

J Clin Med 2022 Apr 20;11(9). Epub 2022 Apr 20.

1st Department of Otolaryngology, Head & Neck Surgery, Aristotle University of Thessaloniki, 54636 Thessaloniki, Greece.

Objective: The aim of this study was to investigate the long-term oncologic outcome and review the state of the art in the management of olfactory neuroblastomas.

Material And Methods: The records of all patients treated for olfactory neuroblastomas in two academic departments between 1975 and 2012 were evaluated retrospectively. Data on epidemiological parameters were collected (age, gender), along with staging (Kadish, Morita), histologic grading (Hyams), time and form of treatment, locoregional control, and disease-specific and overall survival. Read More

View Article and Full-Text PDF

Minimally invasive pericranial flap harvest through a supraorbital eyebrow craniotomy: Technical note in salvage skull base reconstruction.

Clin Neurol Neurosurg 2022 06 26;217:107266. Epub 2022 Apr 26.

Pacific Neuroscience Institute, Santa Monica, CA, USA; Saint John's Cancer Institute, Providence Saint John's Health Center, Santa Monica, CA, USA. Electronic address:

Background And Importance: The supraorbital eyebrow craniotomy is a minimally invasive approach that provides access to pathologies of the anterior and middle cranial fossae. Vascularized flaps are preferred when considering reconstructive options, however, small incisions may not provide adequate access to vascularized tissue. We present two cases demonstrating a modified technique for harvesting pericranium through an eyebrow supraorbital craniotomy for reconstruction of large skull base defects. Read More

View Article and Full-Text PDF

Nasoethmoidal Schwannoma as a Mimicar of Esthesioneuroblastoma: A Case Report and Literature Review.

Neurol India 2022 Mar-Apr;70(2):784-787

Department of Otorhinolaryngology, Guru Gobind Singh Medical College and Hospital, Faridkot, Punjab, India.

Nasoethmoidal schwannomas are rare lesions and their presentation with intracranial extension is even rarer. Here, a patient presenting with rhinorrhea, epistaxis, and proptosis of left eye was diagnosed with giant nasoethmoidal schwannoma extending to frontal lobe and orbit, which was managed with bifrontal craniotomy with endoscopic transnasal gross total excision. This being predominantly a benign lesion has good prognosis if total excision is achieved. Read More

View Article and Full-Text PDF

Transcription Factor Expression in Sinonasal Neuroendocrine Neoplasms and Olfactory Neuroblastoma (ONB): Hyams' Grades 1-3 ONBs Expand the Spectrum of SATB2 and GATA3-Positive Neoplasms.

Endocr Pathol 2022 Jun 6;33(2):264-273. Epub 2022 May 6.

Unit of Pathology, Dept. of Medicine and Surgery, University of Insubria, via O. Rossi 9, 21100, Varese, Italy.

Sinonasal neuroendocrine neoplasms (SN-NENs) are rare and mostly include neuroendocrine carcinoma (NEC), whereas neuroendocrine tumor (NET) is exceptional in this site. Olfactory neuroblastoma (ONB) is a malignant neuroectodermal neoplasm arising in the nasal cavity. Albeit crucial for correct patients' management, the distinction of high grade ONB from NEC is challenging and requires additional diagnostic markers. Read More

View Article and Full-Text PDF

Case Report: Esthesioneuroblastoma Involving the Optic Pathways.

Front Surg 2022 19;9:875881. Epub 2022 Apr 19.

Department of Neurosurgery, AC Camargo Cancer Center, São Paulo, Brazil.

Olfactory neuroblastoma, or esthesioneuroblastoma, is an uncommon malignant tumor originating from the neural crest that commonly occurs in the upper nasal cavity. Its ectopic origin is extremely rare, especially when located in the optical pathways. This paper reports the case of a giant ectopic esthesioneuroblastoma of the optic pathways that were surgically treated through a cranio-orbital-zygomatic (COZ) craniotomy with extensive resection, in addition to a literature review. Read More

View Article and Full-Text PDF

Impact of esthesioneuroblastoma treatment delays on overall patient survival.

Laryngoscope 2022 Apr 23. Epub 2022 Apr 23.

Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine, California, USA.

Objectives: To characterize clinical factors associated with esthesioneuroblastoma treatment delays and determine the impact of these delays on overall survival.

Study Design: Retrospective database analysis.

Methods: The 2004-2016 National Cancer Database was queried for patients with esthesioneuroblastoma managed by primary surgery and adjuvant radiation. Read More

View Article and Full-Text PDF

Management of Esthesioneuroblastoma: A Retrospective Study of 6 Cases and Literature Review.

Case Rep Oncol 2022 Jan-Apr;15(1):176-186. Epub 2022 Mar 10.

Faculty of Medicine and Pharmacy, Sidi Mohammed Ben-Abdellah University, Fes, Morocco.

The esthesioneuroblastoma (ENB) is a rare malignant sinonasal tumor of neuroectodermal origin. This study aimed to improve the understanding of the clinical features by reviewing the literature and analyzing the medical records of patients diagnosed with ENB in our institution between 2012 and 2019. A total of 6 cases of ENB were available for analysis. Read More

View Article and Full-Text PDF

Combined Nasal Endoscopic and Subfrontal Craniotomy for Resection Tumors of Anterior Skull Base.

J Craniofac Surg 2022 Mar-Apr 01;33(2):588-591

Department of Otolaryngology, Cho Ray Hospital, Ho Chi Minh City, Vietnam.

Objective: Sinonasal tumors invading anterior skull base is difficult to treat in Otorhinolaryngology and Neurosurgery. Treatment requires the collaboration of ear, nose and throat (ENT) and neurosurgeon to remove the tumor completely. This study was to evaluate the outcome of combined technique nasal endoscopic and subfrontal approach in case of sinonasal tumors involving anterior skull base. Read More

View Article and Full-Text PDF

Long-term oncologic outcomes in esthesioneuroblastoma: An institutional experience of 143 patients.

Int Forum Allergy Rhinol 2022 Apr 6. Epub 2022 Apr 6.

Department of Otolaryngology-Head and Neck Surgery, Mayo Clinic School of Medicine, Rochester, Minnesota, USA.

Objective: Esthesioneuroblastoma (ENB) is a rare malignant neoplasm arising from the olfactory epithelium of the cribriform plate. The goal of this study was to update our oncologic outcomes for this disease and explore prognostic factors associated with survival.

Materials And Methods: We performed a retrospective analysis of patients with ENB treated at a single tertiary care institution from January 1, 1960, to January 1, 2020. Read More

View Article and Full-Text PDF

Percutaneous Cryoablation for Recurrent Head and Neck Tumors.

Cardiovasc Intervent Radiol 2022 Jun 4;45(6):791-799. Epub 2022 Apr 4.

Service d'Imagerie Interventionnelle, Hôpitaux Universitaires de Strasbourg, 1, place de l'hopital, 67000, Strasbourg, France.

Purpose: To report techniques and results of 16 cryoablation procedures in 11 patients treated for recurrent head and neck cancer.

Methods And Materials: This retrospective study reviewed 11 consecutive patients with head and neck cancer recurrence after primary treatment by surgery and radiotherapy, treated with cryoablation between 2016 and 2020. Efficacy was measured by local control rate evaluated on MRI or/and PET. Read More

View Article and Full-Text PDF

Olfactory Neuroblastoma: Re-Evaluating the Paradigm of Intracranial Extension and Cyst Formation.

Diagnostics (Basel) 2022 Mar 1;12(3). Epub 2022 Mar 1.

Neuroradiology Section, Department of Radiological Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA.

The purpose of the current study was to assess the prevalence of cyst formation at the brain-tumor interface in olfactory neuroblastoma. We used the UCLA patient-based Pathology and Radiology Head and Neck Database (UPP&R HAND) to identify the largest patient cohort reported to date with imaging and pathology data. Eighteen of thirty-one patients (58. Read More

View Article and Full-Text PDF

How I do it: endonasal transcribriform approach for resection of esthesioneuroblastoma.

Acta Neurochir (Wien) 2022 Jul 16;164(7):1949-1952. Epub 2022 Mar 16.

Department of Neurosurgery, Clinical Neurosciences Center, University of Utah, 175 N. Medical Drive East, Salt Lake City, UT, 84132, USA.

Background: Olfactory neuroblastoma, also known as esthesioneuroblastoma, accounts for only 3-6% of sinonasal malignancies but confers a 40% 5-year overall survival.

Method: The authors describe techniques for the endonasal, minimally invasive resection of an esthesioneuroblastoma in a 69-year-old man who presented with headaches and anosmia and describe surgical nuances and their effect on adjuvant therapy planning.

Conclusion: This approach, along with microsurgical techniques, helped increase tumor visualization, improved marginal resection, and reduced surgical risk, which may improve patient outcomes. Read More

View Article and Full-Text PDF

Esthesioneuroblastoma presenting with orbital signs and ectopic adrenocorticotropic hormone syndrome.

Proc (Bayl Univ Med Cent) 2022 15;35(2):245-247. Epub 2021 Nov 15.

Department of Pathology, Baylor Scott & White Health System, Waco, Texas.

A 23-year-old woman with known nasal polyps and a recent seizure presented with diplopia, proptosis, extraocular motility deficits, and stigmata of Cushing syndrome. Computed tomography showed a left sinonasal mass extending into the left orbit. Laboratory evaluation revealed refractory hypokalemia and significantly elevated adrenocorticotropic hormone. Read More

View Article and Full-Text PDF
November 2021

Cystic Intracranial Recurrence of Olfactory Neuroblastoma without Accumulation on Fluorine-18-fluorodeoxyglucose Positron Emission Tomography.

Acta Med Okayama 2022 Feb;76(1):93-98

Department of Neurosurgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University.

A 66-year-old man underwent multimodal treatment for olfactory neuroblastoma (ONB). When he was 72 years old, a cystic intracranial lesion without accumulation on fluorine-18-fluorodeoxyglucose positron emission tomography was detected. Surgical resection was performed when the patient was 73 years old. Read More

View Article and Full-Text PDF
February 2022

Association of Race, Ethnicity, and Socioeconomic Status With Esthesioneuroblastoma Presentation, Treatment, and Survival.

OTO Open 2022 Jan-Mar;6(1):2473974X221075210. Epub 2022 Feb 9.

Department of Otolaryngology-Head and Neck Surgery, Columbia University Irving Medical Center, NewYork-Presbyterian Hospital, New York, New York, USA.

Objective: Socioeconomic and other demographic factors are associated with outcomes in head and neck cancer. This study uses a national cancer database to explore how patient race, ethnicity, and socioeconomic status (SES) are associated with esthesioneuroblastoma outcomes, including 5-year disease-specific survival (DSS), conditional DSS, stage at diagnosis, and treatment.

Study Design: Retrospective cohort analysis. Read More

View Article and Full-Text PDF
February 2022

Prognostic value of microvessel density and its correlation with clinicopathological features in human olfactory neuroblastoma.

Clin Neuropathol 2022 May-Jun;41(3):114-121

Although angiogenesis plays an important role in tumor growth and invasion, its role in the progression of olfactory neuroblastoma (ONB) has rarely been published. The aim of the present research was to analyze the prognostic role of microvessel density (MVD) in ONB and its association with clinicopathological parameters. 70 ONB cases were assessed for immunohistochemical expression of CD31, CD34, CD105, VEGF, and VEGFR2. Read More

View Article and Full-Text PDF

Less common extracerebral tumors.

Authors:
Jeremy C Ganz

Prog Brain Res 2022 6;268(1):279-302. Epub 2022 Jan 6.

Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway. Electronic address:

This chapter examines the results of GKNS on a variety of extraparenchymal skull base tumors some benign and some malignant. For the benign tumors there is good evidence on the effectiveness of the method for pretty much all diagnoses. For malignant extraparenchymal tumors the results are more limited and GKNS only has a supportive role in these lesions. Read More

View Article and Full-Text PDF

Olfactory Neuroblastoma Managed with Endoscopic Sinus Surgery.

J Pharm Bioallied Sci 2021 Nov 10;13(Suppl 2):S1728-S1732. Epub 2021 Nov 10.

Department of Otorhinolaryngology-Head and Neck Surgery, Alhada Armed Forces Hospital, Taif, Saudi Arabia.

Olfactory neuroblastoma (ONB) or esthesioneuroblastoma is a rare malignancy of the nose and paranasal sinuses that originates from the upper nasal vault. We report a rare case of ONB in a 27-year-old female patient with a 2-year history of nasal obstruction, sneezing, nasal discharge, and left eye protrusion. The patient was successfully treated with endoscopic sinus surgery and adjuvant radiotherapy (RT) with 5-year follow-up duration. Read More

View Article and Full-Text PDF
November 2021

Esthesioneuroblastoma with recurrent dural metastases: Long-term multimodality treatment and considerations.

Surg Neurol Int 2021 8;12:606. Epub 2021 Dec 8.

Center for Skull Base Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States.

Background: Esthesioneuroblastoma (ENB) is a rare malignant disease and treatment protocols have not been standardized, varying widely by disease course and institutional practices. Management typically includes wide local excision through open or endoscopic resection, followed by radiotherapy, chemotherapy, and stereotactic radiosurgery. Tumor control can differ on a case-by-case basis. Read More

View Article and Full-Text PDF
December 2021

Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma.

Eur J Cancer 2022 02 31;162:221-236. Epub 2021 Dec 31.

Royal National Ear, Nose and Throat Hospital and Head and Neck Centre, University College London Hospitals NHS Trust, London, UK.

Introduction: Olfactory neuroblastoma (ONB) is a rare cancer of the sinonasal region. We provide a comprehensive analysis of this malignancy with molecular and clinical trial data on a subset of our cohort to report on the potential efficacy of somatostatin receptor 2 (SSTR2)-targeting imaging and therapy.

Methods: We conducted a retrospective analysis of 404 primary, locally recurrent, and metastatic olfactory neuroblastoma (ONB) patients from 12 institutions in the United States of America, United Kingdom and Europe. Read More

View Article and Full-Text PDF
February 2022

Emerging concepts in sinonasal tumor research.

Curr Opin Otolaryngol Head Neck Surg 2022 Feb;30(1):33-39

Sinonasal and Skull Base Tumor Program, National Institute on Deafness and Other Communication Disorders, National Institutes of Health; Bethesda, Maryland.

Purpose Of Review: Sinonasal malignancies are rare and understudied, often diagnosed at late stages, and may behave aggressively. This review explores investigative diagnostic, therapeutic, and scientific advances specific to sinonasal undifferentiated carcinoma (SNUC), intestinal-type adenocarcinoma (ITAC), and olfactory neuroblastoma (ONB).

Recent Findings: A number of studies have recently contributed more robust knowledge of the genetic and molecular landscapes of SNUC, ITAC, and ONB. Read More

View Article and Full-Text PDF
February 2022

A case of olfactory neuroblastoma and literature review.

Asian J Surg 2022 Feb 23;45(2):832-833. Epub 2021 Dec 23.

Clinical School of Ningxia Medical University, Yinchuan, China.

View Article and Full-Text PDF
February 2022

Radiotherapy of sinonasal cancers.

Cancer Radiother 2022 Feb-Apr;26(1-2):156-167. Epub 2021 Dec 22.

Département de radiothérapie, centre François-Baclesse, 3, avenue Général-Harris, 14000 Caen, France; Réseau d'expertise français sur les cancers ORL rares (Refcor), 75000 Paris, France; Groupe d'oncologie radiothérapie des cancers de la tête et du cou (Gortec), 37000 Tours, France. Electronic address:

We present the update of the recommendations of the French society of radiotherapy and oncology on the indications and the technical methods of carrying out radiotherapy of sinonasal cancers. Sinonasal cancers (nasal fossae and sinus) account for 3 to 5% of all cancers of the head and neck. They include carcinomas, mucosal melanomas, sarcomas and lymphomas. Read More

View Article and Full-Text PDF
February 2022

Influence of facility volume and type on esthesioneuroblastoma treatment and outcomes.

Int Forum Allergy Rhinol 2021 Dec 15. Epub 2021 Dec 15.

Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, CA.

View Article and Full-Text PDF
December 2021